ADAM | Evaluate

December 09, 2016

Ash roundup – Progress in intractable leukaemia and a multiple myeloma target

Revisiting a predictor of failure in the post-Celator world

December 03, 2015

Event – Threshold hopes to buck the F-R rule

August 27, 2014

Event – Bull case for Sunesis set on Valor

July 09, 2014

Ireland tax shelter beckons for Salix

February 14, 2013

Ten oncology companies to avoid

August 31, 2012

Amyloid beta focus – Three solanezumab questions that Lilly must answer

July 17, 2009

Vertex's novel financing causes intrigue

May 16, 2008

Event - Elan nervous ahead of bapineuzumab data?